SecSonar.com

Protalix BioTherapeutics, Inc. (PLX)

Protalix BioTherapeutics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Protalix BioTherapeutics, Inc. (PLX) is a Biotechnology company based in US with a market capitalization of $170.4M. Revenue declined 1.2% year-over-year and free cash flow was negative at -$13.6M. This page tracks PLX's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 213 employees · IPO May 15, 1998

Valuation

Valuation & price

$1.98 · as of May 17, 2026 · -37.1% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

3.53

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$3.06$2.22$1.38Jul 25Dec 25Jul 26Jul 7, 25$1.47Jul 9, 25$1.53Jul 11, 25$1.41Jul 15, 25$1.38Jul 17, 25$1.50Jul 21, 25$1.52Jul 23, 25$1.60Jul 25, 25$1.51Jul 29, 25$1.46Jul 31, 25$1.46Aug 4, 25$1.50Aug 6, 25$1.48Aug 11, 25$1.61Aug 13, 25$1.61Aug 15, 25$1.48Aug 19, 25$1.53Aug 21, 25$1.58Aug 25, 25$1.60Aug 27, 25$1.60Aug 29, 25$1.55Sep 3, 25$1.60Sep 5, 25$1.54Sep 9, 25$1.72Sep 11, 25$1.74Sep 16, 25$1.95Sep 18, 25$1.86Sep 22, 25$2.04Sep 24, 25$2.06Sep 26, 25$2.06Sep 30, 25$2.22Oct 2, 25$2.34Oct 6, 25$2.60Oct 8, 25$2.57Oct 10, 25$2.36Oct 14, 25$2.37Oct 16, 25$2.40Oct 21, 25$2.14Oct 23, 25$2.31Oct 27, 25$2.38Oct 29, 25$2.37Oct 31, 25$2.37Nov 4, 25$2.34Nov 6, 25$2.22Nov 10, 25$2.13Nov 12, 25$2.14Nov 14, 25$1.86Nov 18, 25$1.88Nov 20, 25$1.74Nov 25, 25$1.79Nov 28, 25$1.78Dec 2, 25$1.67Dec 4, 25$1.75Dec 8, 25$1.74Dec 10, 25$1.80Dec 12, 25$1.79Dec 16, 25$1.81Dec 18, 25$1.80Dec 22, 25$1.79Dec 24, 25$1.77Dec 29, 25$1.79Jan 2, 26$1.74Jan 6, 26$1.77Jan 8, 26$2.00Jan 12, 26$2.10Jan 14, 26$2.06Jan 16, 26$2.04Jan 21, 26$2.07Jan 23, 26$2.08Jan 27, 26$2.12Jan 29, 26$2.07Feb 2, 26$2.60Feb 4, 26$2.90Feb 9, 26$2.80Feb 11, 26$2.92Feb 13, 26$2.97Feb 18, 26$2.98Feb 20, 26$3.06Feb 24, 26$3.00Feb 26, 26$3.01Mar 2, 26$3.03Mar 4, 26$2.83Mar 6, 26$2.62Mar 10, 26$2.90Mar 12, 26$2.79Mar 17, 26$2.79Mar 19, 26$2.23Mar 23, 26$2.13Mar 25, 26$2.16Mar 27, 26$2.14Mar 31, 26$2.17Apr 2, 26$2.15Apr 7, 26$2.19Apr 9, 26$2.28Apr 13, 26$2.29Apr 15, 26$2.38Apr 17, 26$2.32Apr 22, 26$2.20Apr 24, 26$2.18Apr 28, 26$2.12Apr 30, 26$2.15May 4, 26$2.13May 6, 26$2.02May 8, 26$1.94May 12, 26$1.91May 14, 26$2.00May 18, 26$1.91May 20, 26$2.01May 22, 26$2.10May 28, 26$2.10Jun 1, 26$2.06Jun 3, 26$1.96Jun 5, 26$1.99Jun 9, 26$1.98Jun 11, 26$2.05Jun 15, 26$2.06Jun 17, 26$2.02Jun 22, 26$2.16Jun 24, 26$2.24Jun 26, 26$2.30Jul 2, 26$2.32
$1.3852-week range$3.15
Loading valuation history…

Fundamentals

Key fundamentals

$170.4M

Market cap

-1.2%

Revenue growth (YoY)

47.9%

Gross margin

-$13.6M

Free cash flow (USD)

-$22M

Net debt

Net cash position

8.3%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$9.2MFY 2017$21.1MFY 2018$34.2MFY 2019$54.7MFY 2020$62.9MFY 2021$38.4MFY 2022$47.6MFY 2023$65.5MFY 2024$53.4MFY 2025$52.7M
$9.2M$52.7M

Free cash flow by year

2016 → 2025

FY 2016$-32.9MFY 2017$-11.0MFY 2018$-8.4MFY 2019$-20.0MFY 2020$-26.8MFY 2021$-11.7MFY 2022$-25.6MFY 2023$-2.5MFY 2024$7.4MFY 2025$-13.6M
-$32.9M-$13.6M

Gross margin by year

2021 → 2025

FY 202157.4%FY 202258.9%FY 202364.9%FY 202454.5%FY 202547.9%
57.4%47.9%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 13, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventStock Incentive Plan AmendedJun 25, 2026Filing
  • 8-K eventRegulatory Milestone PaymentMay 21, 2026Filing
  • 8-K eventEarnings ReleaseMay 13, 2026Filing
  • Quarterly report10-Q FiledMay 13, 2026Filing

Questions

Frequently asked questions

What is Protalix BioTherapeutics, Inc.'s market cap?

Protalix BioTherapeutics, Inc. (PLX) has a market capitalization of $170.4M.

What is PLX's P/E ratio?

A meaningful P/E ratio is not available for PLX — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is PLX's price-to-book (P/B) ratio?

PLX trades at 3.53 times book value per share.

Are insiders buying PLX stock?

SEC Form 4 filings show no open-market insider buys at Protalix BioTherapeutics, Inc. in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

PRQR

ProQR Therapeutics N.V.

$168.6M

IFRX

InflaRx N.V.

$175.9M

SPRO

Spero Therapeutics, Inc.

$163.3M

ORMP

Oramed Pharmaceuticals Inc.

$162.9M

AVTX

Avalo Therapeutics, Inc.

$179.1M

VXRT

Vaxart, Inc.

$159.3M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.